Search clinical trials for: Pneumococcal conjugate vaccine

Total 10765 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Pneumococcal Infections

United States, Canada, Denmark, Finland, Israel, Spain
PATH

Completed

Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers

Pneumonia, Pneumococcal

Kenya
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
National Institutes for Food and Drug Control, China; Simoon Record Pharma... and other collaborators

Unknown

Safety Study of 15-Valent Pneumococcal Conjugate Vaccine in Healthy Volunteers Aged Above 2 Months

Pneumonia, Pneumococcal

China
Public Health England
Imperial College London; Institute of Child Health

Withdrawn

Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants (PINC)

Vaccination | Immunization

United Kingdom
LG Chem

Completed

A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

Pneumococcal Infection

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Pneumococcal Infections
CHU de Quebec-Universite Laval
GlaxoSmithKline; Canadian Immunization Research Network

Completed

Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization

Meningococcal Infections
PATH

Completed

Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants

Pneumococcal Disease

Gambia
GlaxoSmithKline

Completed

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Infections, Streptococcal

Poland, Germany, Czechia, Spain
GlaxoSmithKline

Completed

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Argentina, Panama, Colombia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
GlaxoSmithKline
Aeras

Completed

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

Tuberculosis

Gambia
GlaxoSmithKline

Completed

Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib

Infections, Streptococcal

Netherlands
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)

Pneumococcal Infections | Streptococcus Pneumoniae Infection
GlaxoSmithKline
London School of Hygiene and Tropical Medicine; PATH; Medical Research Council... and other collaborators

Completed

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants

Infections, Streptococcal

Gambia
Pfizer

Completed

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Pneumococcal Infections

United States
GlaxoSmithKline

Completed

Impact of Pneumococcal Conjugate Vaccines on Otitis Media and Acute Otitis Media in Swedish Children

Otitis Media | Acute Otitis Media

Sweden
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Infections, Streptococcal

Finland, France, Poland
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide

Transplant-Related Cancer

United States
GlaxoSmithKline

Completed

Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants

Infections, Streptococcal

Germany, Czechia, Sweden, Poland
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC

Completed

A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Pneumococcal Infections
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Virus Diseases | Bacterial Infections
MCM Vaccines B.V.

Completed

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
Prof. Elizabeth Miller

Completed

Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the Accelerated United Kingdom Schedule at 2, 3 and 4 Months (P13UK)

Streptococcus Pneumoniae

United Kingdom
Public Health England
Institute of Child Health; National Institute of Biological Standards and Control

Completed

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life (Sched2)

Pneumococcal Infections | Meningococcal Infections

United Kingdom
NICHD Neonatal Research Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Immunogenicity of PCV-7 Vaccine in VLBW Infants (PCV-7)

Pneumococcal Infections | Streptococcus Pneumoniae | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, Newborn

United States
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)

Pneumococcal Infections
MCM Vaccines B.V.
Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi Company

Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Virus Diseases | Bacterial Infections | Neisseria Meningitidis
GlaxoSmithKline

Terminated

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Influenza

Norway
Korea University Guro Hospital

Completed

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults

HIV/AIDS | Streptococcal Pneumonia
Duke University
Centers for Disease Control and Prevention; Kaiser Permanente

Completed

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Fever | Febrile Seizure | Fever After Vaccination

United States
Kameda Medical Center
Merck Sharp & Dohme LLC; PPD; Osaka University

Completed

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Influenza | Pneumococcal Pneumonia

Japan
GlaxoSmithKline

Completed

Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A

Infections, Streptococcal

Czechia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Finland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Celgene Corporation

Completed

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Multiple Myeloma

United States
GlaxoSmithKline

Completed

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

Infections, Streptococcal

Poland, Philippines
Pfizer

Completed

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

United States, Spain, France, Canada, Germany, Czechia, Sweden, Belgium, Poland, Netherlands
Pfizer

Completed

Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants

Healthy Subjects

Japan
GlaxoSmithKline

Completed

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Infections, Streptococcal

Chile
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants

Infections, Streptococcal

Spain, Greece
GlaxoSmithKline

Completed

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali

Infections, Streptococcal

Mali
Merck Sharp & Dohme LLC

Completed

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Pneumococcal Infections
Region Skane
Lund University

Completed

Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar® (PVA)

Rheumatoid Arthritis | Spondylarthropathy

Sweden
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Poland, Philippines
Pfizer
Kaiser Permanente

Completed

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

Invasive Pneumococcal Disease

United States
LimmaTech Biologics AG

Completed

Phase I to Test a New Pneumococcal Vaccine

Pneumonia, Bacterial | Pneumococcal Pneumonia

Germany
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Virus Diseases | Bacterial Infections

3

Subscribe